About Edesa Biotech, Inc.
https://www.edesabiotech.comEdesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs.
CEO
Pardeep Nijhawan FRCPC,
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-10-11 | Reverse | 1:7 |
| 2019-06-10 | Reverse | 1:6 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
STONEPINE CAPITAL MANAGEMENT, LLC
Shares:687.5K
Value:$996.88K
VELAN CAPITAL INVESTMENT MANAGEMENT LP
Shares:687.5K
Value:$996.88K
RUBRIC CAPITAL MANAGEMENT LP
Shares:687.5K
Value:$996.88K
Summary
Showing Top 3 of 26
About Edesa Biotech, Inc.
https://www.edesabiotech.comEdesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $0 | $2.44M ▲ | $-2.23M ▼ | 0% | $-0.32 ▼ | $-2.2M ▼ |
| Q3-2025 | $0 | $1.9M ▲ | $-1.75M ▼ | 0% | $-0.25 ▲ | $-1.69M ▼ |
| Q2-2025 | $0 | $1.64M ▼ | $-1.59M ▲ | 0% | $-0.3 ▲ | $-1.57M ▲ |
| Q1-2025 | $0 | $1.9M ▲ | $-1.62M ▼ | 0% | $-0.48 ▼ | $-1.57M ▼ |
| Q4-2024 | $0 | $1M | $-962.05K | 0% | $-0.3 | $-917.84K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $10.79M ▼ | $13.66M ▼ | $1.21M ▲ | $12.45M ▼ |
| Q3-2025 | $12.36M ▼ | $14.8M ▼ | $672.67K ▼ | $14.13M ▼ |
| Q2-2025 | $13.9M ▲ | $16.45M ▲ | $914.7K ▼ | $15.54M ▲ |
| Q1-2025 | $1.56M ▲ | $4.16M ▲ | $1.9M ▲ | $2.26M ▲ |
| Q4-2024 | $1.04M | $3.81M | $1.83M | $1.98M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-2.23M ▼ | $-1.77M ▼ | $0 | $244.38K ▲ | $-1.57M ▼ | $-1.72M ▲ |
| Q3-2025 | $-1.75M ▼ | $-1.75M ▲ | $0 | $216.92K ▼ | $-1.53M ▼ | $-1.75M ▲ |
| Q2-2025 | $-1.59M ▲ | $-2.33M ▼ | $0 | $14.77M ▲ | $12.33M ▲ | $-2.33M ▼ |
| Q1-2025 | $-1.62M ▼ | $-1.52M ▼ | $0 | $2.07M ▲ | $526.18K ▲ | $-1.52M ▼ |
| Q4-2024 | $-962.05K | $-967.04K | $0 | $-31.43K | $-1M | $-967.04K |
Revenue by Products
| Product | Q3-2018 | Q4-2018 | Q1-2019 | Q2-2019 |
|---|---|---|---|---|
 Product | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Pardeep Nijhawan FRCPC,
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-10-11 | Reverse | 1:7 |
| 2019-06-10 | Reverse | 1:6 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
STONEPINE CAPITAL MANAGEMENT, LLC
Shares:687.5K
Value:$996.88K
VELAN CAPITAL INVESTMENT MANAGEMENT LP
Shares:687.5K
Value:$996.88K
RUBRIC CAPITAL MANAGEMENT LP
Shares:687.5K
Value:$996.88K
Summary
Showing Top 3 of 26